Physician profile
John D Hart
NPI 1871089748
$2,798.27
in general payments reported to CMS, 2019-2025
31 companies · $703 in 2025
The $703 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.87 · 2022: $253 · 2023: $783 · 2024: $1,043 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.36 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $565.58 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $196.10 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $188.76 | 2022-2025 | Breztri, Airsupra |
| Abbvie INC. | $186.99 | 2023-2025 | |
| Novo Nordisk INC | $184.61 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $171.04 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $137.23 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $135.13 | 2022-2025 | |
| Exact Sciences Corporation | $132.36 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $106.82 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $95.43 | 2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.28 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $58.69 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $52.84 | 2022-2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.40 | 2023-2024 | Trulance, Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $48.92 | 2024-2025 | Voquezna |
| Qiagen, LLC | $46.03 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.13 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $41.73 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Corcept Therapeutics | $39.64 | 2024 | Korlym |
| Vertex Pharmaceuticals Incorporated | $34.09 | 2025 | |
| Astellas Pharma US INC | $33.96 | 2024 | Veozah |
| Cequr Corporation | $28.33 | 2024-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.17 | 2023 | Jardiance |
| Gilead Sciences, INC. | $22.66 | 2024 | Epclusa |
| Novartis Pharmaceuticals Corporation | $20.02 | 2024 | |
| Medtronic, INC. | $17.08 | 2024 | Linq II |
| Rgh Enterprises LLC | $16.18 | 2025 | |
| Averitas Pharma INC. | $15.16 | 2024 | Qutenza |
| Alkermes, INC. | $14.80 | 2022 | |
| Axsome Therapeutics, INC. | $14.11 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.